<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03312595</url>
  </required_header>
  <id_info>
    <org_study_id>17-RES-001</org_study_id>
    <nct_id>NCT03312595</nct_id>
  </id_info>
  <brief_title>Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)</brief_title>
  <official_title>Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) A Case Series of Initial Effectiveness and Safety Measures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acera Surgical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acera Surgical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the outcomes of patients who receive a&#xD;
      certain type of skin substitute called RestrataTM Wound Matrix (Restrata™). Results of this&#xD;
      study may be used to make decisions on whether to conduct additional studies on this&#xD;
      particular wound matrix product. RestrataTM has been cleared by the Food and Drug&#xD;
      Administration for use in certain types of ulcer treatments, including the type that will be&#xD;
      part of this study (diabetic foot ulcers).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Control Group: None (Utilize historical / published data on outcomes using standard of care)&#xD;
&#xD;
      Test Group: Treatment of DFUs with RestrataTM Wound Matrix&#xD;
&#xD;
      Study Type: Interventional&#xD;
&#xD;
      Study Design: Allocation: Non-randomized Endpoint Classification: Efficacy Intervention&#xD;
      Model: Direct assignment Masking: Single Blind (Subject) Primary Purpose: Treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2017</start_date>
  <completion_date type="Actual">July 30, 2018</completion_date>
  <primary_completion_date type="Actual">July 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Wound Closed</measure>
    <time_frame>Up to 14 weeks</time_frame>
    <description>from baseline at week 0 to 14 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Wound Area From Baseline</measure>
    <time_frame>Baseline and weekly for up to 14 weeks</time_frame>
    <description>Wound area measurements will be made via tracing acetate every week for 14 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Wound Closure</measure>
    <time_frame>Baseline up to 14 weeks</time_frame>
    <description>The number of weeks until complete closure is first identified will be determined for each patient who has been deemed completely closed within the 14 week treatment period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Restrata TM Wound Matrix</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Prospective, single armed, non-randomized study with direct assignment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restrata TM Wound Matrix</intervention_name>
    <description>The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds</description>
    <arm_group_label>Restrata TM Wound Matrix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female age 18 or older&#xD;
&#xD;
          -  Patient's ulcer must be diabetic in origin, located at least in part on the plantar&#xD;
             surface and larger than 1cm2 after the run-in period. Debridement will be done prior&#xD;
             to randomization. Subject's informed consent for participating in this study, must be&#xD;
             obtained prior to proceeding with sharp debridement&#xD;
&#xD;
          -  Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes&#xD;
             mellitus per ADA).&#xD;
&#xD;
          -  Ulcer must be present for a minimum of four weeks before enrollment/randomization,&#xD;
             with documented failure of prior treatment to heal the wound. A two-week run in period&#xD;
             will precede enrollment/randomization in the trial to document the indolent nature of&#xD;
             the patients selected&#xD;
&#xD;
          -  Patient does not exhibit clinical signs / symptoms of infection upon gross observation&#xD;
             (at least 3 of the following: pain, redness, purulence, exudate, temperature) or have&#xD;
             been diagnosed with an active infection at time of screening&#xD;
&#xD;
          -  Patient is willing to provide informed consent and is willing to participate in all&#xD;
             procedures and follow up evaluations necessary to complete the study&#xD;
&#xD;
          -  Patient has adequate control of diabetes, as demonstrated by one of the following&#xD;
             within 30 days of screening:&#xD;
&#xD;
               -  HbA1c &lt; 12%&#xD;
&#xD;
               -  Serum Creatinine &lt; 3.0mg/dl&#xD;
&#xD;
          -  Patient has adequate circulation to the affected extremity, as demonstrated by one of&#xD;
             the following within the past 60 days of the first screening visit:&#xD;
&#xD;
               -  Dorsum transcutaneous oxygen test (TcPO2) with results&#xD;
&#xD;
                  ≥30mmHg, OR&#xD;
&#xD;
               -  ABIs with results of ≥0.7 and ≤1.5, OR&#xD;
&#xD;
               -  Doppler arterial waveforms, which are triphasic or biphasic at the ankle of&#xD;
                  affected leg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with an ulcer probing to bone (UT Grade IIIA-D)&#xD;
&#xD;
          -  Patients whose index diabetic foot ulcers are greater than 25cm2&#xD;
&#xD;
          -  Patient has an additional wound within 3cm of the study wound&#xD;
&#xD;
          -  Patients not in reasonable metabolic control&#xD;
&#xD;
          -  Patients with a known history of poor compliance with medical treatments&#xD;
&#xD;
          -  Patients who have been previously enrolled into this study, or are presently&#xD;
             participating in a clinical trial with DFU indications&#xD;
&#xD;
          -  Patients with known or suspected local skin malignancy to the index diabetic ulcer&#xD;
&#xD;
          -  Patients diagnosed with autoimmune connective tissues diseases&#xD;
&#xD;
          -  Patients that have received a graft material on the study ulcer within the previous 30&#xD;
             days&#xD;
&#xD;
          -  Patients who are pregnant or breast feeding&#xD;
&#xD;
          -  Patients who are taking medications that are considered immune system modulator&#xD;
&#xD;
          -  Study wound has closed &gt; 30% over the two-week run-in period&#xD;
&#xD;
          -  Patients with a known allergy to resorbable suture materials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Associated Foot &amp; Ankle Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Reginal Medical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAVAHCS</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Foot Care And Clinical Research Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard C. Galperin, DPM</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 1, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <results_first_submitted>February 22, 2021</results_first_submitted>
  <results_first_submitted_qc>April 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2021</results_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03312595/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Restrata Wound Matrix</title>
          <description>Prospective, single armed, non-randomized study with direct assignment&#xD;
Restrata Wound Matrix: The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Restrata Wound Matrix</title>
          <description>Prospective, single armed, non-randomized study with direct assignment&#xD;
Restrata Wound Matrix: The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Data not consistently reported for all patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Data not consistently reported for all patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Wound Closed</title>
        <description>from baseline at week 0 to 14 weeks</description>
        <time_frame>Up to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restrata Wound Matrix</title>
            <description>Prospective, single armed, non-randomized study with direct assignment&#xD;
Restrata Wound Matrix: The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Wound Closed</title>
          <description>from baseline at week 0 to 14 weeks</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Wound Area From Baseline</title>
        <description>Wound area measurements will be made via tracing acetate every week for 14 weeks.</description>
        <time_frame>Baseline and weekly for up to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restrata Wound Matrix</title>
            <description>Prospective, single armed, non-randomized study with direct assignment&#xD;
Restrata Wound Matrix: The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Wound Area From Baseline</title>
          <description>Wound area measurements will be made via tracing acetate every week for 14 weeks.</description>
          <units>% wound area change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Wound Closure</title>
        <description>The number of weeks until complete closure is first identified will be determined for each patient who has been deemed completely closed within the 14 week treatment period.</description>
        <time_frame>Baseline up to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restrata Wound Matrix</title>
            <description>Prospective, single armed, non-randomized study with direct assignment&#xD;
Restrata Wound Matrix: The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Wound Closure</title>
          <description>The number of weeks until complete closure is first identified will be determined for each patient who has been deemed completely closed within the 14 week treatment period.</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3.5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Restrata Wound Matrix</title>
          <description>Prospective, single armed, non-randomized study with direct assignment&#xD;
Restrata Wound Matrix: The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Deemed not due to Restrata Wound Matrix.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>Deemed not due to Restrata Wound Matrix.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <description>Deemed not due to Restrata Wound Matrix.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <description>Deemed not due to Restrata Wound Matrix.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <description>Deemed not due to Restrata Wound Matrix.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <description>Deemed not due to Restrata Wound Matrix.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>New ulcer</sub_title>
                <description>Deemed not due to Restrata Wound Matrix.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Science Officer</name_or_title>
      <organization>Acera Surgical, Inc.</organization>
      <phone>844-879-2237</phone>
      <email>information@acera-surgical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

